Abstract:OBJECTIVE:To evaluate the impact of histology on efficacy of pemetrexed in Chinese non-small cell lung cancer (NSCLC) patients. This report summarized the results of two clinical trials of pemetrexed in Chinese patients with advanced NSCLC in 2nd line setting and maintenance setting after 1st line (JMID study and Chinese subgroup from JMEN study) treatment.METHODS:For the Chinese JMID study (second-line), Chinese patients with locally advanced or metastatic (stage IIIA, IIIB or IV) NSCLC who had prior chemotherapy were enrolled. The study was designed to investigate the noninferiority of pemetrexed (500 mg/m(2), day 1 of each 21-day cycle) to docetaxel (75 mg/m(2), day 1 of each 21-day cycle) in terms of overall survival (OS). For the global JMEN study (maintenance), patients initially diagnosed with IIIB or IV NSCLC, those who had not progressed after completing at least four cycles of platinum-based chemotherapy were enrolled to test for the superiority of pemetrexed (500 mg/m(2), day 1 of each 21-day cycle) over placebo with progression free survival (PFS) as primary endpoint.RESULTS:In JMID study, the OS was similar between the pemetrexed group (Pem group) and docetaxel group (Doc group). Retrospective histological subtype analysis showed survival benefits (both OS and PFS) numerically of non-squamous patients over squamous patients in the Pem group (OS: HR 0.74, 95% CI 0.45-1.21, P = 0.2267, median 11.7 vs. 9.7 months; PFS: HR 0.77, 95% CI 0.44-1.34, P = 0.3585, median 3.0 vs. 1.7 months). In the Chinese subgroup of JMEN study, the median PFS in the Pem group for squamous and nonsquamous patients was 4.2 and 1.5 months for squamous patients, the median OS in the Pem group for squamous and nonsquamous patients was 22.5 and 6.2 months for squamous patients. In JMEN China subgroup analysis, the HR on histology was not analyzed due to the small sample size. In terms of safety profile, drug-related grade 3 or 4 hematological toxicities (leukocytopenia and neutropenia) events occurring after second-line treatment were significantly lower in the Pem group than in the Doc group (both P < 0.001). Similarly in patients receiving pemetrexed maintenance after first-line treatment, incidences of toxicity events were low.CONCLUSIONS:Consistent with global results, in Chinese NSCLC patients, histology has an impact on the efficacy of pemetrexed, in which non-squamous histology predicts a positive outcome for patients treated with pemetrexed. In terms of overall safety, pemetrexed is better than docetaxel with a lower incidence of adverse events and anticipates manageable safety profile in NSCLC patients. Based on consistent Chinese data from the two studies, pemetrexed is recommended as a standard chemotherapy regime in both second-line and maintenance setting after first-line treatment for Chinese non-squamous NSCLC patients.

Effectiveness and Safety of Pemetrexed Versus Docetaxel As a Treatment for Advanced Non-Small Cell Lung Cancer: a Systematic Review and Meta-Analysis.

Efficacy of Pemetrexed Plus Platinum Doublet Chemotherapy As First-Line Treatment for Advanced Nonsquamous Non-Small-cell-lung Cancer: a Systematic Review and Meta-Analysis.

Effectiveness and safety of pemetrexed versus docetaxel as a treatment for advanced non-small cell lung cancer: a systematic review and meta-analysis.

Comparison of the Curative Effects of Pemetrexed and Docetaxel in Patients with Non-Small-cell Lung Cancer

Meta-analysis on platinum plus pemetrexed or docetaxel in treatment of non-small cell lung cancer

Pemetrexed plus platinum in non-small cell lung cancer:a Meta analysis of randomized controlled trials

[A Randomized, Controlled, Multicenter Clinical Trial Comparing Pemetrexed/cisplatin and Gemcitabine/cisplatin As First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer].

Efficacy and Safety of Pemetrexed Compared with Docetaxel As Second-Line Treatment in Elderly Patients with Advanced Non-Squamous Non-Small-cell Lung Cancer

The Efficacy and Safety of Pemetrexed-Based Doublet Therapy Compared to Pemetrexed Alone for the Second-Line Treatment of Advanced Non-Small-cell Lung Cancer: an Updated Meta-Analysis

[A Meta-Analysis of Pemetrexed Plus Platinum Chemotherapy Versus Gemcitabine Plus Platinum Chemotherapy for Advanced Non-Small Cell Lung Cancer].

Effect and safety of second-line pemetrexed in patients with advanced large cell lung cancer

[The Efficacy and Safety of Pemetrexed As Monotherapy for Chinese Patients with Advanced Non-Small Cell Lung Cancer].

Second-line Pemetrexed Versus Docetaxel in Chinese Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Randomized, Open-Label Study

Clinical efficacy of pemetrexed in the treatment of non-small cell lung cancer with asymptomatic brain metastasis

Survival Without Common Toxicity Criteria Grade 3/4 Toxicity Following Second-Line Treatment with Pemetrexed for Nonsquamous Non-Small Cell Lung Cancer in Chinese Patients

[Impact of Histology on Efficacy of Pemetrexed: Pemetrexed in Second-Line Setting and As Maintenance Therapy after First-Line Treatment in Chinese Patients with Advanced NSCLC].

The clinical effects of pemetrexed or docetaxel combined with cisplatin as the first line treatment for advanced lung adenocarcinoma

A Cost-Effectiveness Analysis of Docetaxel Versus Pemetrexed in Second-Line Chemotherapy for Stage IIIb or IV Non-Small Cell Lung Cancer in China

[Efficacy and Toxicity of Pemetrexed or Gemcitabine Combined with Cisplatin in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer].

Pemetrexed Monotherapy Versus Pemetrexed Plus Platinum Combination As Second-Line Treatment for Advanced Non-Small Cell Lung Cancer

Supplementary Material For: A Cost-Effectiveness Analysis of Docetaxel Versus Pemetrexed in Second-Line Chemotherapy for Stage IIIb or IV Non-Small Cell Lung Cancer in China